Skip to main content

Post-IPO Equity Biotechnology Companies

Explore 483 biotechnology startups that raised post-ipo equity funding. Access verified founder contact information and fundraising data.

Total Companies
483
Total Funding
$3.8B
Avg Funding
$150.5M
Cities
18

Export 483 Post-IPO Equity Biotechnology Companies

Get founder emails, funding data, and company details in one CSV

Start Free Trial

Recently Funded Companies

Export
Toronto, Canada
$50.0M
raised

Helus Pharma is a biopharmaceutical company that develops psychedelic therapeutics for mental health conditions.

Sep 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Waltham, United States
$380.0M
raised

Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases including Alzheimer’s.

Sep 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

London, United Kingdom
$393K
raised

New treatment for blood diseases, such as leukemia and lymphoma.

Sep 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Palo Alto, United States
$150.0M
raised

MapLight Therapeutics is a biopharma company that offers a platform designed to discover and develop therapeutics for brain disorders.

Aug 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

New York, United States
$150.0M
raised

LB Pharmaceuticals specializes in developing LB-102 (n-Methyl amisulpride) as a treatment for schizophrenia.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Ready to Reach These Founders?

Get verified contact info for decision-makers at 483 funded startups

41,000+ verified emails
Unlimited exports
No credit card required
Würzburg, Germany
$23.2M
raised

Pentixapharm develop PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Alameda, United States
$7.5M
raised

Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR molecules.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Cambridge, United States
$375.1M
raised

Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

South San Francisco, United States
$240.0M
raised

Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Redwood City, United States
$132.0M
raised

Jasper Therapeutics is a biotechnology company that develops novel antibody therapies for stem cell transplants.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Ready to Reach These Founders?

Get verified contact info for decision-makers at 483 funded startups

41,000+ verified emails
Unlimited exports
No credit card required
Vancouver, Canada
$1.1M
raised

Publicly traded (RKV.V) company focused on the development of new cancer treatments based on novel DNA-damage response technologies.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Pittsburgh, United States
$972K
raised

Sharp Therapeutics is engaged in the development of biosensors for cellular biology research and high-throughput screening.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Cambridge, United States
$200.0M
raised

Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

San Diego, United States
$632.5M
raised

Erasca is a developer of oncology drugs intended to provide precision oncology options.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Los Altos, United States
$100.0M
raised

Alto Neuroscience is a clinical-stage biopharmaceutical company that creates precision medicines through its AI-driven biomarker platform.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Ready to Reach These Founders?

Get verified contact info for decision-makers at 483 funded startups

41,000+ verified emails
Unlimited exports
No credit card required
Englewood Cliffs, United States
$11.7M
raised

Silo Pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

London, United Kingdom
$3.3M
raised

Virax Biolabs is a biotechnology company focusing on the prevention, detection, and diagnosis of viral diseases.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Cambridge, United States
$50.0M
raised

Cue Biopharma is a developer of a productive platform for the treatment of cancer and autoimmune disease.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Boca Raton, United States
$8.5M
raised

Grid AI delivers innovative energy management solutions for homes, businesses, and industrial campuses.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Cambridge, United States
$15.0M
raised

Elicio Therapeutics is a pharmaceutical research company that develops an immuno-tumor vaccine to treat cancer.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Ready to Reach These Founders?

Get verified contact info for decision-makers at 483 funded startups

41,000+ verified emails
Unlimited exports
No credit card required
Palo Alto, United States
$1.0B
raised

BridgeBio focuses on the development and commercialization of precision medicines for various genetic diseases and cancers.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

New York, United States
$125.0M
raised

Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Fort Lee, United States
$100.0M
raised

Nuvectis Pharma is a biopharmaceutical company intended to develop novel targeted therapeutics for the treatment of cancer.

Jun 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Houston, United States
$3.0M
raised

FibroBiologics is a regenerative medicine company developing an innovative solution for chronic disease treatment using fibroblast cells.

Jun 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Cambridge, United States
$3.5M
raised

Decoy Therapeutics is a biotech company that design the next generation of peptide conjugate therapies to protect and expand patient lives.

Jun 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Showing 26 to 50 of 483 companies

Ready to Connect with Post-IPO Equity Biotechnology Startups?

Get verified founder emails, funding details, and company data for 483 post-ipo equity biotechnology companies.

Get Started - Access Contact Information

Join thousands of sales teams, investors, and service providers using VCBacked

483 Biotechnology Post-IPO Equity Startups (November 2026) — Page 2 | VCBacked